Previous Article
Journal of Virology, December 1998, p. 10323-10327, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Human Lymphoblastoid CD4+ T Cells
Become Permissive to Macrophage-Tropic Strains of Human
Immunodeficiency Virus Type 1 after Passage into Severe Combined
Immunodeficient Mice through In Vivo Upregulation of CCR5: In Vivo
Dynamics of CD4+ T-Cell Differentiation in Pathogenesis
of AIDS
Caterina
Lapenta,
Stefania
Parlato,
Massimo
Spada,
Stefano
M.
Santini,
Paola
Rizza,
Mariantonia
Logozzi,
Enrico
Proietti,
Filippo
Belardelli, and
Stefano
Fais*
Laboratory of Virology, Istituto Superiore di
Sanità, Viale Regina Elena 299, 00161 Rome, Italy
Received 29 June 1998/Accepted 26 August 1998
 |
ABSTRACT |
In this article, we show that passage in SCID mice rendered a human
CD4+ T-cell line (CEM cells) highly susceptible to
infection by macrophage-tropic (M-tropic) strains and primary clinical
isolates of human immunodeficiency virus type 1 (HIV-1). This in
vivo-acquired permissiveness of CEM cells was associated with the
induction of a CD45RO+ phenotype as well as of some
-chemokine receptors. Regulated upon activation, normal T-cell
expressed and secreted chemokine entirely inhibited the ability of
M-tropic HIV-1 strains to infect these cells. These findings may lead
to new approaches in investigating in vivo the capacity of different
HIV strains to exploit chemokine receptors in relation to the dynamics
of the activation and/or differentiation state of human
CD4+ T cells.
 |
TEXT |
Understanding the scenario of in
vivo interactions between human immunodeficiency virus type 1 (HIV-1)
and target cells is an issue of crucial importance in AIDS research.
However, progress in this area has been hampered by the problems in
reconciling the results obtained in studies using in vitro cell systems
with the events occurring under in vivo conditions and, possibly, with those observed in HIV-1-infected patients. In particular,
overestimating the significance of in vitro virus-target cell assays
for determining viral tropism and pathogenicity may lead to misleading
conceptions about HIV-1 pathogenesis, if it is not sufficiently taken
into account that the phenotypes of both virus and target cells can significantly change in the course of in vivo infection. This obviously
has profound implications for viral transmission, pathogenesis, and
disease progression. For this reason and due to the general confusion
created by the present classification systems, some authors have
recently proposed that a new HIV-1 classification based on the
coreceptor usage rather than in vitro assays is needed (2).
The susceptibility to infection with different HIV-1 strains is related
to the expression of various chemokine receptors on T-lymphocyte
subsets (1-4, 7, 8, 14). In fact, CXCR4 (the principal
coreceptor for T-cell tropic [T-tropic] HIV-1 strains) is mainly
expressed on naive CD4+ T lymphocytes (CD45RA), while CCR5
(the principal coreceptor for macrophage-tropic [M-tropic] HIV-1
strains) is predominantly expressed on memory CD4+ T
lymphocytes (CD45RO) (3). Although some studies have
suggested that the progressive differentiation of human
CD4+ T cells toward a memory phenotype is associated with
an increased susceptibility to HIV-1 infection (21, 24, 27),
there is no direct in vivo evidence on the relationships between T-cell differentiation and the importance of coreceptor usage for HIV-1 cell
tropism and HIV-1 induced disease.
Human-severe combined immunodeficient (SCID) mouse xenografts represent
unique and practical in vivo models with which to study the early
events triggered by the interaction of HIV-1 with the human immune
system (11-13, 15-18). In the present study, we investigated the possible changes in the permissiveness to various HIV-1 strains of a human CD4+ T-cell line (CEM-SS)
(19) after transplantation into SCID mice.
Acquired susceptibility to the M-tropic HIV-1 strain SF162 by
CEM cells grown in SCID mice.
We first compared the
abilities of syncytium-inducing T-tropic (IIIB) and
non-syncytium-inducing M-tropic (SF162) strains of HIV-1 to
infect CEM cells in vitro and after transplantation into SCID
mice. CB.17 SCID/SCID female mice were injected subcutaneously (s.c.)
in the shoulder with 20 × 106 uninfected CEM-SS cells
resuspended in 0.2 ml of RPMI 1640 (22). SCID mice were
treated with a monoclonal anti-mouse granulocyte antibody to deplete
animals of some residual reactivity, as previously described
(22). The in vivo HIV-1 infection of CEM-SCID mice was
performed by a simultaneous s.c. injection of 20 × 106
uninfected CEM-SS cells (American Type Culture Collection,
Rockville, Md.) with 106 50% tissue culture infective
doses of cell-free virus (10). The virus stocks were derived
from clarified culture medium of phytohemagglutinin-interleukin
2-stimulated HIV-1-infected peripheral blood mononuclear cells, frozen
at
140°C. Titers were determined by standard end-point dilution
methods. The viral strains used in these experiments were HIV-1
IIIB and HIV-1 SF162. Under all conditions, the HIV-1-infected
chimeras were sacrificed when the tumors reached 20- to 25-mm mean
diameter and analyzed for the virus replication at the tumor site and
p24 antigenemia. At sacrifice, the CEM cell tumors were excised,
and single-cell suspension was obtained as described (22).
Cell suspensions were subjected to HIV-1 DNA PCR, as described
(20), and HIV-1 reverse transcription-PCR (RT-PCR)
with specific primers was performed to detect all viral RNAs,
as reported elsewhere (10). Sera of infected animals were tested for HIV p24 antigen by an antigen capture enzyme-linked immunosorbent assay (Dupont, Bruxelles, Belgium). For HIV-1 in vitro
infection, cells were pelleted and incubated with the virus inoculum at
multiplicity of infection of 0.1 for 1 h at 37°C, washed three
times, and cultured in complete medium. As shown in Fig.
1A (left), HIV-1 SF162 did not infect the
parental CEM cells maintained under in vitro condition up to 2 weeks
after challenge, while these cells were fully permissive to HIV-1 IIIB. In contrast to the results of in vitro experiments, the in vivo infection induced a productive infection with both HIV-1 strains. In
fact, high levels of p24 antigenemia (Fig. 1A, right) were detected in
the sera of xenografted animals infected with both SF162 and III-B
HIV-1 strains up to 2 months after the in vivo virus challenge.
Moreover, the DNA PCR and RT-PCR analyses of CEM cells obtained from
s.c. tumors showed high levels of HIV-1 infection with both HIV-1
strains (Fig. 1B). These results strongly suggested that the SCID mouse
environment had induced important changes in CEM cells, rendering them
permissive to a broader spectrum of HIV-1 strains.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 1.
Acquired susceptibility to infection with the SF162
strain of HIV-1 by CEM cells grown in SCID mice. (A) p24 antigen levels
in the supernatants of CEM cells infected in vitro with either IIIB
(white columns) or SF162 (black columns) strain (left) and in sera of
SCID mice transplanted s.c. with CEM cells and simultaneously infected
with either IIIB (white columns) or SF162 (black columns) (right).
Histograms represent the means ± standard errors for six samples.
(B) HIV-1 infection of CEM cell tumors grown in SCID mice. DNA PCR for
gag-specific sequences (top row). The detection range of
proviral copy number was determined in parallel by amplifying known
amounts of 8E5 cell line DNA. RT-PCR (middle row) was performed with
specific primers to detect all viral RNAs. 2-Microglobulin ( 2
mg) RT-PCR (bottom row) was run in parallel to normalize the levels of
human RNA in all the samples. Single animals (A1 through A4 and B1
through B3), negative control (NC), and positive control (8E5) are
indicated.
|
|
Characterization of CEM cell phenotype in SCID mice.
We next
characterized the phenotype of ex vivo CEM cells as compared to the
parental cells. CEM cells obtained from uninfected s.c. tumors were
analyzed by flow cytometry by using the following monoclonal
antibodies: anti-CD45RA fluorescein isothiocyanate and anti-CD45RO
phycoerythrin (PE) (Becton Dickinson, San José, Calif.),
anti-CXCR4 PE, and anti-CCR5 PE (Pharmingen, San Diego, Calif.). Cells
were fixed with 2% paraformaldehyde and analyzed on a FACSORT
cytometer (Becton Dickinson) equipped with a 488-nm argon laser. Data
were recorded and analyzed by using LYSIS II software (Becton
Dickinson). The results, summarized in Fig.
2A, show that CEM cells obtained from the
s.c. tumors grown in SCID mice (ex vivo CEM cells) differed
significantly from the parental CEM cells. In particular, (i) ex
vivo CEM cells were CD45RO+ while the parental cells
were CD45RO
, (ii) the ex vivo CEM cells expressed
low level of CCR5 on the cell membrane while the parental CEM cells
were all negative for CCR5 (staining with control PE-conjugated
antibodies did not show nonspecific binding on ex vivo CEM cells
[data not shown]), and (iii) the percentages of
CXCR4+ cells did not show significant differences between
ex vivo and parental CEM cells. CD45RA, CD3, and CD4 were equally
expressed in both the parental and ex vivo CEM cells (data not shown).
To further explore the phenotype of ex vivo CEM cells we used
RT-PCR analysis. mRNAs coding for human chemokine receptors (CCR2,
CCR3, CXCR4, and CCR5) were detected in CEM cells by amplifying
the RNA isolated as previously described (20) with specific
primer pairs. The following primer sequences were used for
CXCR4: 5' TGCTGTATGTCTCGTGGTAGG and 3'
TGTAGGTGCTGAAATCAACCC. Primers specific for CCR5, CCR2, and
CCR3 are reported elsewhere (6, 9). The samples were
amplified for 30 to 35 cycles under the following conditions: 94°C
for 40 s, 62°C for 40 s, and 72°C for 40 s.
2-Microglobulin RT-PCR (20) was run in parallel to normalize the levels of
human RNA in all the samples. Preliminary experiments were performed to
verify that the human primers used did not cross-react with murine
sequences. All RT-PCR products were in the linear range of
amplification (data not shown). The results of the RT-PCR analysis of
the HIV-1 coreceptors were consistent with the flow cytometry results.
In fact, a marked upregulation of CCR2, CCR3, and CCR5 mRNAs occurred
in the ex vivo CEM cells as compared to the parental cells, while the
mRNA for CXCR4 was equally expressed in the two cell types (Fig. 2B).
Notably, RT-PCR analysis showed that the ex vivo CEM cells
progressively lost their new phenotype when maintained under in vitro
conditions for a few weeks. In fact, at 30 days of in vitro culture,
the expression of CCR2, CCR3, and CCR5 mRNAs of these cells was
virtually identical to that of the original parental cells (Fig.
2B), while the expression of CXCR4 mRNA did not change during the
culture period (Fig. 2B). These changes paralleled a progressive loss
of the CD45RO phenotype for ex vivo CEM cells occurring at 2 to 3 weeks of in vitro culture (data not shown). Taken together, these data
indicated that the phenotype of ex vivo CEM cells markedly differed
from that of parental cells. This could be the result of either a
progressive differentiation of CEM cells due to the stimuli present in
the mouse environment or an expansion of a very small fraction of CEM
cells (expressing the CD45RO phenotype and higher levels of chemokine
receptors) in SCID mice. This hypothesis may appear possible given the
results for CCR5, which is detectable (at the mRNA level) in parental
CEM cells. However, it seems unlikely in the view of the fact that
CD45RO and the other chemokine receptors (with the exception of CXCR4)
are not expressed in parental CEM cells.

View larger version (14K):
[in this window]
[in a new window]

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 2.
Time course of phenotypic changes of ex vivo CEM cells.
(A) Flow cytometric analysis of parental CEM cells (dotted lines) and
of CEM cells obtained from s.c. tumors grown in SCID mice (ex vivo CEM
cells) (solid lines) labeled with anti-CD45RO, anti-CCR5, and
anti-CXCR4 antibodies. (B) RT-PCR in parental (P) and ex vivo CEM
cells. The results of one representative experiment are shown. Ex vivo
CEM cells were collected and analyzed immediately after harvesting (0)
and at 6, 12, and 30 days of in vitro culture. RNA was amplified with
primer pairs for CCR2, CCR3, CXCR4, and CCR5.
|
|
HIV-1 infection of ex vivo CEM cells and role of
-chemokine
receptors.
We then characterized the spectrum of permissiveness of
ex vivo CEM cells to HIV-1 infection, by challenging these cells with SF162, IIIB, and two primary clinical isolates (G and PD, kindly provided by Maria Capobianchi, Institute of Virology, University "La
Sapienza," Rome, Italy), as compared to the parental CEM cells. Ex
vivo CEM cells were cultured in RPMI 1640 medium supplemented with 10%
heat-inactivated fetal calf serum. Cells were seeded at 2 × 105/ml and passaged every three days. For HIV-1 in vitro
infection, parental and ex vivo CEM cells were pelleted and incubated
with the virus inoculum at multiplicity of infection of 0.1 for 1 h at 37°C, washed three times, and cultured in complete medium. The
results of these experiments were consistent with the in vivo findings
illustrated in Fig. 1, in that the ex vivo CEM cells remained highly
permissive to both SF162 and IIIB strains whereas the parental CEM
cells did not efficiently integrate and replicate the
non-syncytium-inducing M-tropic HIV-1 strain SF162, even at 12 days
after the challenge (Fig. 3A). Moreover,
the ex vivo CEM cells were efficiently infected by both the primary
clinical isolates (Fig. 3A). Notably, the finding that no proviral
HIV-1 copies were detected after infection of parental CEM cells with
HIV-1 SF-162 (Fig. 3A) renders it unlikely that our data simply reflect an in vivo selection of a small fraction of preexisting CEM cells permissive for M-tropic HIV-1 strains. As shown in Fig. 3B, the permissiveness of the ex vivo CEM cells to SF162 progressively declined
during in vitro culture. These results suggested that the acquired
permissiveness of ex vivo CEM cells was dependent on the HIV-1
coreceptors gained in vivo, in that both the newly acquired coreceptor
phenotype and the permissiveness to the M-tropic strain were
progressively lost during in vitro culture. To verify whether the
upregulation of the
-chemokine receptors on the ex vivo CEM cells
had a role in their acquired permissiveness to M-tropic HIV-1
strains, we tested whether the
-chemokines regulated upon
activation, normal T-cell expressed and secreted chemokine (RANTES), macrophage inflammatory protein 1
(MIP-1
), MIP-1
, and monocyte chemotactic protein 1 (MCP-1) could interfere with the
entry, integration, and replication of SF162 in these cells. For these
experiments, recombinant human RANTES, MIP-1
, MIP-1
(R&D Systems,
Minneapolis, Minn.), and MCP-1 (PeproTech, EC, Ltd., London, United
Kingdom) were each added at 300 ng/ml to the cells together with the
virus inoculum and at every passage in culture. Controls were
cultured in complete medium without supplements. PCR analysis
clearly showed that RANTES exerted an early inhibitory effect on viral
entry. Treatment with this
-chemokine resulted in undetectable
levels of HIV-1 proviral copies in ex vivo CEM cells (Fig. 3C, left).
MIP-1
exerted a slight inhibitory effect on SF162 infection, while
little or no effect was observed with either MIP-1
or the CCR2
ligand MCP-1 (Fig. 3C, left). RT-PCR analysis of HIV-1 RNA
confirmed that RANTES virtually abolished SF162 replication in
the ex vivo CEM cells (Fig. 3C, right). These results confirmed that
the slight increase in CCR5 expression in ex vivo CEM cells shown by
flow cytometry (Fig. 2) was key in rendering these cells permissive to
HIV-1 SF162 strain.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 3.
Permissiveness of ex vivo CEM cells to infection with
M-tropic HIV-1 strains and effects by -chemokines. (A) PCR analysis
of HIV-1 proviral DNA in parental and ex vivo CEM cells. Parental and
ex vivo CEM cells were infected in vitro with the HIV-1 IIIB (lane a)
or SF162 (lane c) strain or with each of two primary clinical isolates
(lanes b and d). DNA samples were analyzed for HIV-1 proviral DNA at 12 days after the virus challenge. Negative controls (NC) and positive
controls (8E5) were also processed. (B) Time course of permissiveness
of ex vivo CEM cells to the HIV-1 SF162 strain. Ex vivo CEM cells were
infected with HIV-1 SF162 immediately after harvesting (0) and after 6, 12, and 30 days of in vitro culture and analyzed for the presence of
proviral DNA by PCR at 3 days after virus challenge. (C) Effects of the
various chemokines on the infection of ex vivo CEM cells with the HIV-1
SF162 strain. Ex vivo CEM cells were infected in vitro with HIV-1 SF162
and cultured with and without (Ctr) the addition of the chemokines
RANTES, MIP-1 , MIP-1 , and MCP-1. Samples were analyzed for the
presence of HIV-1 proviral DNA (left) and RNA (right) by PCR at 3 days
after the infection. HLA-DQ DNA PCR and
2-microglobulin ( 2 mg) RT-PCR were run in parallel to normalize
the levels of human DNA and RNA, respectively, in all the samples. The
results are representative of four separate experiments.
|
|
Some studies have shown that CD4+ T lymphocytes expressing
the memory phenotype are infectable with a broad spectrum of HIV-1 strains, while naive CD4+ T cells are exclusively
permissive to T-tropic strains of HIV-1 and require cellular activation
signals for productive infection (21, 23, 24, 27). This
phenomenon has recently been elucidated by the demonstration that naive
T cells predominantly express CXCR4 HIV-1 coreceptor while memory T
cells express CCR5 (3). In vitro studies have largely
confirmed that human CD4+ T-cell lines are exclusively
permissive to T-tropic HIV-1 strains through CXCR4 usage
(2). The data presented here indicate that the passage of a
human CD4+ T-cell line into SCID mice markedly changed the
phenotype of these cells, rendering them permissive to both an M-tropic
strain and primary clinical isolates of HIV-1, which did not enter the parental cells maintained in vitro. This permissiveness was associated with the acquisition of a memory phenotype and was mostly dependent on
the availability of the CCR5 HIV-1 coreceptor, since the occupancy of
this receptor by RANTES and MIP-1
, its natural ligands, markedly inhibited the SF162 infection. Thus, the changes induced by the SCID
mouse environment were responsible for the acquired permissiveness of
CEM cells to the M-tropic HIV-1 strain, SF162. This suggests that the
dynamics of activation and differentiation of CD4+ T cells,
induced by antigen stimulation or merely maintained by environmental
factors (20, 25, 26), may continuously influence the
emergence of different viral phenotypes during the development of HIV-1
infection and the progression to AIDS (3, 21, 23, 24, 27).
Notably, different from peripheral blood lymphocytes, the great
majority of CD4+ T cells in the mucosal tissues exhibit the
memory phenotype (5) and, therefore, are potentially
susceptible to the infection with a broad spectrum of HIV-1 strains. In
this study, we have shown that a specific environmental factors of SCID
mice may induce differentiation stimuli even for a T-cell line,
rendering these cells permissive to the so-called R5 viruses
(2) through the specific upregulation of CCR5 HIV-1
coreceptor. These data emphasize the need for a new classification of
HIV-1 strains based on coreceptor use (2) rather than on
other parameters such as the cell target (M-tropic or T-tropic), the
capacity to induce syncytia in cell lines (syncytium inducing or
non-syncytium inducing), or the growth kinetics in culture (slow/low
level or rapid/high level).
New concepts regarding both the early events of HIV-1 infection and the
mechanisms leading to the CD4+ T-cell depletion occurring
in AIDS patients may stem from experiments performed with human/SCID
mouse xenograft models. Our model offers new opportunities for a
practical in vivo investigation, under highly controlled conditions, of
mechanisms of HIV-1 infection in relation to the dynamics of activation
and differentiation of human CD4+ T cells.
 |
ACKNOWLEDGMENTS |
We are indebted to Angela Lippa for secretarial assistance.
This work was supported by grants from the Italian Ministry of Health
(Progetto di Ricerca sull'AIDS 1997, 10A/L).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratory of
Virology, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy. Phone: 396 49903294. Fax: 396 49387184. E-mail:
Fais{at}iss.it.
 |
REFERENCES |
| 1.
|
Alkhatib, G.,
C. Combadiere,
C. C. Broder,
Y. Feng,
P. E. Kennedy,
P. M. Murphy, and E. A. Berger.
1996.
CC CKR5: a RANTES, MIP-1 , MIP-1 receptor as a fusion cofactor for macrophage-tropic HIV-1.
Science
272:1955-1958[Abstract].
|
| 2.
|
Berger, E. A.,
R. W. Doms,
E. M. Fenyo,
B. T. M. Korber,
D. Littman,
J. P. Moore,
Q. J. Sattentau,
H. Schuitemaker,
J. Sodrosky, and R. A. Weiss.
1998.
A new classification for HIV-1.
Nature
391:240[Medline].
|
| 3.
|
Bleul, C. C.,
L. Wu,
J. A. Hoxie,
T. A. Springer, and C. R. Mackay.
1997.
The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes.
Proc. Natl. Acad. Sci. USA
94:1925-1930[Abstract/Free Full Text].
|
| 4.
|
Clapham, P. R.
1997.
HIV and chemokines: ligands sharing cell-surface receptors.
Trends Cell Biol.
7:264-268.
[Medline] |
| 5.
|
De Maria, R.,
S. Fais,
M. Silvestri,
L. Frati,
F. Pallone,
A. Santoni, and R. Testi.
1993.
Continuous in vivo activation and transient hyporesponsiveness to TcR/CD3 triggering of human gut lamina propria lymphocytes.
Eur. J. Immunol.
23:3104-3108[Medline].
|
| 6.
|
Deng, H.,
R. Liu,
W. Ellmeier,
S. Choe,
D. Unutmaz,
M. Burkhart,
P. Di Marzio,
S. Marmon,
R. E. Sutton, and C. M. Hill.
1996.
Identification of a major co-receptor for primary isolates of HIV-1.
Nature
381:661-666[Medline].
|
| 7.
|
Doranz, B. J.,
J. Rucker,
Y. Yi,
R. J. Smith,
M. Samson,
S. C. Peiper,
M. Parmentier,
R. G. Collman, and R. W. Doms.
1996.
A dual-tropic HIV-1 isolate that uses fusin and the -chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactor.
Cell
85:1149-1158[Medline].
|
| 8.
|
D'Souza, M. P., and V. A. Harden.
1996.
Chemokines and HIV-1 second receptors.
Nat. Med.
12:1293-1300.
|
| 9.
|
Frade, J. M. R.,
M. Llorente,
M. Mellado,
J. Alcamì,
J. C. Gutiérrez-Ramos,
A. Zaballos,
G. del Real, and C. Martìnez-A.
1997.
The amino-terminal domain of the CCR2 chemokine receptor acts as a coreceptor for HIV-1 infection.
J. Clin. Investig.
100:497-502[Medline].
|
| 10.
|
Lapenta, C.,
S. Fais,
P. Rizza,
M. Spada,
M. Logozzi,
S. Parlato,
S. M. Santini,
F. Belardelli, and E. Proietti.
1997.
U937-SCID mouse xenografts: a new model for acute in vivo HIV-1 infection suitable to test antiviral strategies.
Antivir. Res.
36:81-90[Medline].
|
| 11.
|
McCune, J. M.
1988.
The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function.
Science
24:1632-1639.
|
| 12.
|
McCune, J. M.,
R. Namikawa,
C. C. Shih,
L. Rabin, and H. Kaneshima.
1990.
Suppression of HIV infection in AZT-treated SCID-hu mice.
Science
247:564-566[Abstract/Free Full Text].
|
| 13.
|
McCune, J. M.
1997.
Animal models of HIV-1 disease.
Science
278:2141-2142[Free Full Text].
|
| 14.
|
Moore, J. P.,
A. Trkola, and T. Dragic.
1997.
Co-receptors for HIV-1 entry.
Curr. Opin. Immunol.
9:551-562[Medline].
|
| 15.
|
Mosier, D. E.,
R. J. Gulizia,
S. M. Baird, and D. B. Wilson.
1988.
Transfer of functional human immune system to mice with severe combined immunodeficiency.
Nature
335:256-259[Medline].
|
| 16.
|
Mosier, D. E.,
R. J. Gulizia,
S. M. Baird,
D. B. Wilson,
D. H. Spector, and S. A. Spector.
1991.
Human immunodeficiency virus infection of human PBL-SCID mice.
Science
25:791-794.
|
| 17.
|
Mosier, D. E.,
R. J. Gulizia,
P. D. MacIsaac,
B. E. Torbett, and J. A. Levy.
1993.
Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates.
Science
260:689-692[Abstract/Free Full Text].
|
| 18.
|
Namikawa, R.,
H. Kanemisha,
M. Lieberman,
I. L. Weissman, and J. M. McCune.
1991.
Infection of the SCID-hu mouse by HIV-1.
Science
242:1684-1686.
|
| 19.
|
Nara, P. L.,
W. C. Hatch,
N. M. Dunlop,
W. G. Robey,
L. O. Arthur,
M. A. Gonda, and P. J. Fischinger.
1987.
Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody.
AIDS Res. Hum. Retroviruses
3:283-302[Medline].
|
| 20.
|
Rizza, P.,
S. M. Santini,
M. Logozzi,
C. Lapenta,
P. Sestili,
G. Gherardi,
R. Lande,
M. Spada,
S. Parlato,
F. Belardelli, and S. Fais.
1996.
T-cell dysfunctions in hu-PBL-SCID mice infected with human immunodeficiency virus (HIV) shortly after reconstitution: in vivo effects of HIV on highly activated human immune cells.
J. Virol.
70:7958-7964[Abstract].
|
| 21.
|
Roederer, M.,
P. A. Raju,
D. K. Mitra,
L. A. Herzenberg, and L. A. Herzenberg.
1997.
HIV does not replicate in naive CD4 T cells stimulated with CD3/CD28.
J. Clin. Investig.
99:1555-1564[Medline].
|
| 22.
|
Santini, S. M.,
M. Spada,
S. Parlato,
M. Logozzi,
C. Lapenta,
E. Proietti,
F. Belardelli, and S. Fais.
1998.
Treatment of severe combined immunodeficiency (SCID) mice with anti-murine granulocyte monoclonal antibody improves human leukocyte xenotransplantation.
Transplantation
65:416-420[Medline].
|
| 23.
|
Schnittman, S. M.,
H. C. Lane,
J. Greenhouse,
J. S. Justement,
M. Baseler, and A. S. Fauci.
1990.
Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals.
Proc. Natl. Acad. Sci. USA
87:6058-6062[Abstract/Free Full Text].
|
| 24.
|
Spina, C. A.,
H. E. Prince, and D. D. Richman.
1997.
Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro.
J. Clin. Investig.
99:1774-1785[Medline].
|
| 25.
|
Tary-Lehmann, M.,
A. Saxon, and P. V. Lehmann.
1995.
The human immune system in hu-PBL-SCID mice.
Immunol. Today
16:529-533[Medline].
|
| 26.
|
Uittembogaart, C. H.,
D. J. Anisman,
M. Tary-Lehmann,
L. W. Vollger,
T. M. Breit,
J. J. M. Van Dongen, and A. Saxon.
1994.
The SCID mouse environment causes immunophenotypic changes in human immature T-cell lines.
Int. J. Cancer
56:546-551[Medline].
|
| 27.
|
Wood, T. C.,
B. D. Roberts,
S. T. Butera, and T. M. Folks.
1997.
Loss of inducible virus in CD45RA naive cells after human immunodeficiency virus-1 entry accounts for preferential viral replication in CD45RO memory cells.
Blood
89:1635-1641[Abstract/Free Full Text].
|
Journal of Virology, December 1998, p. 10323-10327, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Fais, S., Lapenta, C., Santini, S. M., Spada, M., Parlato, S., Logozzi, M., Rizza, P., Belardelli, F.
(1999). Human Immunodeficiency Virus Type 1 Strains R5 and X4 Induce Different Pathogenic Effects in hu-PBL-SCID Mice, Depending on the State of Activation/Differentiation of Human Target Cells at the Time of Primary Infection. J. Virol.
73: 6453-6459
[Abstract]
[Full Text]